Movatterモバイル変換


[0]ホーム

URL:


CDSCO logo

Central Drugs Standard Control Organization

Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India
swach bharat logo
×
newNotice regarding Guidance for approval Covid-19 vaccine in India for restricted use in emergency situation which are already approved for restricted use by US FDA EMA, UK MHRA, PMDA Japan or which are listed in WHO Emergency use listing15th April,2021DCGI Message 202101 Jan 2021For Medical devices which are under voluntary registrations, the file number generated is the registration number of firm.E-GOV cell at CDSCOCDSCO,HQ accredited with Quality Management Systems IS/ISO 9001:2015 by BIS

Biologics

Hero Banner Images
Hero Banner Images

Biological products, or biologics, are medical products. Many biologics are made from a variety of natural sources (human, animal or microorganism). Like drugs, some biologics are intended to treat diseases and medical conditions. Other biologics are used to prevent or diagnose diseases. Examples of biological products include
  • vaccines
  • blood and blood products for transfusion and/or manufacturing into other products
  • allergenic extracts, which are used for both diagnosis and treatment (for example, allergy shots)
  • human cells and tissues used for transplantation (for example, tendons, ligaments and bone)
  • gene therapies
  • cellular therapies
  • tests to screen potential blood donors for infectious agents such as HIV
  • Grant of NOC for issuance of Form 29 (manufacture of drugs for the purpose of Examination, test or analysis of vaccines)
  • Approval of Clinical Trial.
  • Grant of Marketing Authorization.
  • Grant of Registration Certificate, Import License and Test Licence in Form 11.
  • Approval of Form 28-D Licensing (Vaccines) under CLAA Scheme.
  • Issuance of Export NOC and Permission under Rule 37.
  • Approval of Post Approval Changes.
  • Grant of NOC in Form 29 (manufacture of drugs for the purpose of Examination, test or analysis of r-DNA products).
  • Approval of Clinical Trial.
  • Grant of Marketing Authorization.
  • Grant of Registration Certificate, Import License and Test Licence in Form 11.
  • Approval of Form 28-D Licensing (r-DNA) under CLAA Scheme.
  • Issuance of Export NOC and Permission under Rule 37.
  • Approval of Post Approval Changes.
  • Grant of NOC in Form 29 (manufacture of drugs for the purpose of Examination, test or analysis of Stem cells and Cell based products).
  • Approval of Clinical Trial.
  • Grant of Marketing Authorization.
  • Grant of Registration Certificate, Import License and Test Licence in Form 11.
  • Grant of NOC in Form 29 (manufacture of drugs for the purpose of Examination, test or analysis of Blood & Blood Products).
  • Approval of Clinical Trial.
  • Grant of Marketing Authorization.
  • Grant of Registration Certificate, Import License and Test Licence in Form 11.
  • Approval of Form 28-E Licensing (Blood Products) under CLAA Scheme.
  • Grant of NOC for issuance of Form 29 (manufacture of drugs for the purpose of Examination, test or analysis of Veterinary vaccines)
  • Grant of NOC for field trials.
  • Grant of Marketing Authorization.
  • Grant of Registration Certificate, Import License and Test Licence in Form 11.
  • Approval of Form 28-D Licensing (Veterinary Vaccines) under CLAA Scheme.
  • Issuance of Export NOC and Permission under Rule 37.
  • Approval of Post Approval Changes.

Content is not available.

content not available

S.noTitleRelease DateDownload PdfPdf Size1Biosimilar Guideline 20162020-Feb-072363 KB2NSQ Vi-Conjugate Typhoid Vaccine Batch No.TC010915 and Batch No. TC010417 of M/s Bio Med Pvt Ltd dated 14-03-20182018-Mar-14905KB317list of vaccine manufacturing units inspected-rotated_22018-Feb-091353kb4 1-Revoke order dated 19-08-2015 for the purpose of conducting clinical trial.2015-Aug-1954KB5Sub Standard Quality of Human Albumin IP/EP Albiomin Solution for infusion2015-May-1962KB6Action in pursuance to the investigation carried out at facility (M/s Wellness Solution) for administration of Dendritic cells for treatment of Cancer2014-Aug-2862KB7Action in pursuance to the investigation carried out at M/s Nichi-In Centre for Regenerative Medicine facility for administration of Dendritic Cells for treatment of cancer2014-Aug-2594KB8Action in pursuance to the investigation_Denvax Clinic2013-Jul-23360KB
S.noTitleRelease DateDownload PdfPdf Size12016inpect2018-Feb-231156kb
S.noTitleRelease DateDownload PdfPdf Size1Office Memorandum regarding Clarification of Comprehensive permission for products imported for overprinting/stickering/stamping as per Rule 104A of Drugs and Cosmetics Rules 19452025-May-26438 KB2Inviting comments on Revised Guidelines on Similar Biologics- Regulatory requirements for Marketing Authorization in India, 2025 drafted by CDSCO2025-May-061002 KB3 Update on Information on Convalescent Plasma in COVID-192021-May-2433 KB4Office Memorandum regarding grant of permission for carrying out overprinting/stickering/stamping of imported drugs in certain cases under the provisions of Rule 104A2020-Jan-29540 KB5Revised List of Oxytocin Manufacturer2018-Jun-11425KB6Minutes of the meeting of 14th CBBDTEC2018-Jun-052,853KB7Speical operation to prevent and detect illegal manufacturing of API formulations and Import of oxytocin in India2018-May-21671KB8Office Memorandum regarding speical operation to prevent and detect illegal manufacturing of API formulations and Import of oxytocin in India2018-May-21666KB9notification 19-2015-20202018-Feb-23422kb10Office Memorandum regarding Sampling of imported insuline formulations at port offices2018-Feb-07343KB11Notice regarding Online application for Human Vaccines on Sugam2017-Feb-06270KB12Office Memorandum: Avoiding multiple inspections of a facility using Risk Based Approach2016-Dec-20304KB13Office Memorandum: Issue of Clinical trial permission for r-DNA derived products Dated 20.12.20162016-Dec-20290KB14Circular: NOC for export of biological products (Vaccine & r-DNA products) under form 29 License to manufacture drugs for purposes of examination, test or analysis2016-Dec-13236KB15Office Memorandum: Timeline for CDL Kasauli to review and processing of applications referred for CMC or post appoval change2016-Dec-13269KB16Order: Timeline for communication of recommendation to the stakeholders based on the minutes of meeting of various Committees2016-Dec-13229KB17Office Memorandum: Form 29 license to manufacture drugs for examination, test or analysis for biological products ( Vaccine & r-DNA Products)2016-Dec-13476Kb18Presentation for Rabies Vaccine- regarding2016-Sep-08218KB19Notice dated 26.03.2016 regarding the proposed revised guidelines on Similar Biologics 20162016-Mar-2648KB20Notice dated 23.03.2016 regarding Preparation for global switch from tOPV to bOPV 20162016-Mar-23173KB21Notice2016-Mar-11108KB22Meeting of all Vaccine Manufacutres & Importers on 15th January 20152014-Dec-26513KB23Notice Regarding Approvals of Stem Cells and Cell Based Products Dated 18.02.20142014-Feb-18493KB24Notice dated 08.07.2013:- Revision of CDSCO Guidance for industry for biological products for applications under post approval changes PAC /1108 ver 1.12013-Jul-08508KB25Notice - clarification and requirements related to post approval changes as per CDSCO Guidance for industry for biological products2013-Jan-18603KB
S.noTitleRelease DateDownload PdfPdf Size1List of PUSR meeting172018-Feb-097kb

[8]ページ先頭

©2009-2026 Movatter.jp